

Lois Shepherd

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11990371/publications.pdf>

Version: 2024-02-01

37
papers

5,580
citations

279701

23
h-index

345118

36
g-index

37
all docs

37
docs citations

37
times ranked

6067
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of cardiopulmonary bypass duration on efficacy of fibrinogen replacement with cryoprecipitate compared with fibrinogen concentrate: a post hoc analysis of the Fibrinogen Replenishment in Surgery (FIBRES) randomised controlled trial. <i>British Journal of Anaesthesia</i> , 2022, .	1.5	4
2	A descriptive cost-€analysis of MYX.1/MCRN003, a phase 2 clinical trial evaluating high-€dose weekly carfilzomib, cyclophosphamide, and dexamethasone in relapsed and refractory multiple myeloma. <i>European Journal of Haematology</i> , 2021, 107, 333-342.	1.1	0
3	Effect of Fibrinogen Concentrate vs Cryoprecipitate on Blood Component Transfusion After Cardiac Surgery. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 1966.	3.8	106
4	Can we transfuse wisely in patients undergoing chemotherapy for acute leukemia or autologous stem cell transplantation?. <i>Transfusion</i> , 2019, 59, 2308-2315.	0.8	5
5	A bioclinical prognostic model using MYC and BCL2 predicts outcome in relapsed/refractory diffuse large B-cell lymphoma. <i>Haematologica</i> , 2018, 103, 288-296.	1.7	15
6	Effect of the addition of rituximab to salvage chemotherapy prior to autologous stem cell transplant in aggressive CD20+ lymphoma: a cohort comparison from the NCIC Clinical Trials Group Study LY.12*. <i>Leukemia and Lymphoma</i> , 2017, 58, 64-69.	0.6	11
7	A pharmacogenetic analysis of the Canadian Cancer Trials Group MY.10 clinical trial of maintenance therapy for multiple myeloma. <i>Blood</i> , 2016, 128, 732-735.	0.6	4
8	A four gene signature of chromosome instability (CIN4) predicts for benefit from taxanes in the NCIC-CTG MA21 clinical trial. <i>Oncotarget</i> , 2016, 7, 49099-49106.	0.8	2
9	Salvage chemotherapy and autologous stem cell transplantation for transformed indolent lymphoma: a subset analysis of NCIC CTG LY12. <i>Blood</i> , 2015, 126, 733-738.	0.6	39
10	Defining Breast Cancer Intrinsic Subtypes by Quantitative Receptor Expression. <i>Oncologist</i> , 2015, 20, 474-482.	1.9	145
11	Gemcitabine/Dexamethasone/Cisplatin vs Cytarabine/Dexamethasone/Cisplatin for Relapsed or Refractory Aggressive-Histology Lymphoma: Cost-Utility Analysis of NCIC CTG LY.12. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	3.0	20
12	Thalidomide-prednisone maintenance following autologous stem cell transplant for Multiple Myeloma: effect on thrombin generation and procoagulant markers in NCIC CTG MY.10. <i>British Journal of Haematology</i> , 2015, 168, 511-517.	1.2	11
13	A four gene signature predicts benefit from anthracyclines: evidence from the BR9601 and MA.5 clinical trials. <i>Oncotarget</i> , 2015, 6, 31693-31701.	0.8	6
14	A Framework for Biobank Sustainability. <i>Biopreservation and Biobanking</i> , 2014, 12, 60-68.	0.5	105
15	All-trans retinoic acid and late relapses in acute promyelocytic leukemia: Very long-term follow-up of the North American Intergroup Study I0129. <i>Leukemia Research</i> , 2013, 37, 795-801.	0.4	40
16	A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada Clinicals Trials Group Myeloma 10 Trial. <i>Blood</i> , 2013, 121, 1517-1523.	0.6	137
17	Certification for Biobanks: The Program Developed by the Canadian Tumour Repository Network (CTRNet). <i>Biopreservation and Biobanking</i> , 2012, 10, 426-432.	0.5	45
18	Chromosome 17 centromere (CEP17) duplication as a predictor of anthracycline response: evidence from the NCIC Clinical Trials Group (NCIC CTG) MA.5 Trial. <i>Breast Cancer Research and Treatment</i> , 2012, 131, 541-551.	1.1	19

#	ARTICLE	IF	CITATIONS
19	Does microgranular variant morphology of acute promyelocytic leukemia independently predict a less favorable outcome compared with classical M3 APL? A joint study of the North American Intergroup and the PETHEMA Group. <i>Blood</i> , 2010, 116, 5650-5659.	0.6	33
20	Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. <i>Lancet Oncology</i> , The, 2010, 11, 55-65.	5.1	1,252
21	Treatment of children with acute promyelocytic leukemia: Results of the first North American intergroup trial INT0129. <i>Pediatric Blood and Cancer</i> , 2009, 53, 1005-1010.	0.8	43
22	Decision making in adjuvant trials in breast cancer: the NCIC CTG MA.17 trial as an example. <i>Breast Cancer Research and Treatment</i> , 2008, 108, 265-269.	1.1	7
23	Competing Causes of Death From a Randomized Trial of Extended Adjuvant Endocrine Therapy for Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2008, 100, 252-260.	3.0	156
24	The Ethics of Early Stopping Rules. <i>Journal of Clinical Oncology</i> , 2005, 23, 2862-2863.	0.8	10
25	Risk of Acute Myeloid Leukemia and Myelodysplastic Syndrome in Trials of Adjuvant Epirubicin for Early Breast Cancer: Correlation With Doses of Epirubicin and Cyclophosphamide. <i>Journal of Clinical Oncology</i> , 2005, 23, 4179-4191.	0.8	178
26	Health-related quality of life in survivors of locally advanced breast cancer: an international randomised controlled phase III trial. <i>Lancet Oncology</i> , The, 2005, 6, 287-294.	5.1	44
27	A Randomized Phase III Study of Gemcitabine, Dexamethasone, and Cisplatin Versus Dexamethasone, Cytarabine, and Cisplatin as Salvage Chemotherapy Followed by Posttransplantation Rituximab Maintenance Therapy Versus Observation for Treatment of Aggressive B-Cell and T-Cell Non-Hodgkin's Lymphoma. <i>Clinical Lymphoma and Myeloma</i> , 2005, 6, 56-60.	2.1	14
28	Health-Related Quality of Life Parameters As Prognostic Factors in a Nonmetastatic Breast Cancer Population: An International Multicenter Study. <i>Journal of Clinical Oncology</i> , 2004, 22, 3381-3388.	0.8	118
29	Results of a Multicenter Randomized Phase II Trial of Thalidomide and Prednisone Maintenance Therapy for Multiple Myeloma after Autologous Stem Cell Transplant. <i>Clinical Cancer Research</i> , 2004, 10, 8170-8176.	3.2	63
30	Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma. <i>Cancer</i> , 2004, 101, 1835-1842.	2.0	118
31	Risk of Acute Leukemia Following Epirubicin-Based Adjuvant Chemotherapy: A Report From the National Cancer Institute of Canada Clinical Trials Group. <i>Journal of Clinical Oncology</i> , 2003, 21, 3066-3071.	0.8	90
32	All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol. <i>Blood</i> , 2002, 100, 4298-4302.	0.6	427
33	Therapy-Related Myeloid Leukemias Are Observed in Patients With Chronic Lymphocytic Leukemia After Treatment With Fludarabine and Chlorambucil: Results of an Intergroup Study, Cancer and Leukemia Group B 9011. <i>Journal of Clinical Oncology</i> , 2002, 20, 3878-3884.	0.8	167
34	Analysis of age, estimated creatinine clearance and pretreatment hematologic parameters as predictors of fludarabine toxicity in patients treated for chronic lymphocytic leukemia: a CALGB (9011) coordinated intergroup study. <i>Cancer Chemotherapy and Pharmacology</i> , 2002, 50, 37-45.	1.1	62
35	Impact of Therapy With Chlorambucil, Fludarabine, or Fludarabine Plus Chlorambucil on Infections in Patients With Chronic Lymphocytic Leukemia: Intergroup Study Cancer and Leukemia Group B 9011. <i>Journal of Clinical Oncology</i> , 2001, 19, 3611-3621.	0.8	139
36	Fludarabine Compared with Chlorambucil as Primary Therapy for Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2000, 343, 1750-1757.	13.9	939

#	ARTICLE	IF	CITATIONS
37	All-trans-Retinoic Acid in Acute Promyelocytic Leukemia. New England Journal of Medicine, 1997, 337, 1021-1028.	13.9	1,006